SAN
DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board
of Directors has authorized a new
share repurchase program under which Neurocrine
Biosciences may repurchase up to $500
million of its shares, subject to market conditions. This
new share repurchase authorization is in addition to the
$300 million accelerated repurchase
program that was announced in October
2024 and completed in early February
2025.
William Rastetter, Chairman of
the Board of Directors of Neurocrine Biosciences, said, "This
authorization reflects our approach to capital allocation that
balances driving sustained revenue growth through investing in our
commercial products, INGREZZA and CRENESSITY, advancing our
expanding R&D pipeline and returning capital to
shareholders."
Under the new authorization, repurchases may be made from time
to time at management's discretion through a variety of methods,
such as open-market transactions including pre-set trading plans,
privately negotiated transactions, accelerated share repurchases,
and other transactions in accordance with applicable securities
laws.
About Neurocrine
Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose:
to relieve suffering for people with great needs. We are dedicated
to discovering and developing life- changing treatments for
patients with under-addressed neuropsychiatric, neurological,
and neuroendocrine disorders. The company's
diverse portfolio includes U.S. FDA-approved treatments for tardive
dyskinesia, chorea associated with Huntington's disease, classic
congenital adrenal hyperplasia,
endometriosis* and uterine
fibroids*, as well as a robust pipeline
including multiple compounds in mid-
to late-phase clinical development across our
core therapeutic areas. For three decades,
we have applied our unique insight into neuroscience and
the interconnections between brain and body systems to treat
complex conditions. We relentlessly pursue medicines to ease the
burden of debilitating diseases and disorders, because you deserve
brave science. For more information, visit neurocrine.com, and
follow the company on LinkedIn, X (Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU
DESERVE BRAVE SCIENCE are registered trademarks
of Neurocrine Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements that
involve a number of risks and uncertainties. These statements
include, but are not limited to, statements related to potential
share repurchases and the future performance of Neurocrine
Biosciences. Factors that could cause actual results to differ
materially from those stated or implied in the forward-looking
statements, include but are not limited to the following: whether
we will be able to consummate the contemplated share repurchases in
the amount authorized or at all; constraints, volatility, or
disruptions in the capital markets or other factors affecting our
ability to enter into or complete share repurchases; risks and
uncertainties associated with Neurocrine Biosciences' business and
finances in general; risks and uncertainties associated with the
commercialization of INGREZZA and CRENESSITY; risks related to the
development of our product candidates; risks associated with our
dependence on third parties for development, manufacturing, and
commercialization activities for our products and product
candidates, and our ability to manage these third parties; risks
that the FDA or other regulatory authorities may make adverse
decisions regarding our products or product candidates; risks that
development activities may not be initiated or completed on time or
at all, or may be delayed for regulatory, manufacturing, or other
reasons, may not be successful or replicate previous clinical trial
results, may fail to demonstrate that our product candidates are
safe and effective, or may not be predictive of real-world results
or of results in subsequent clinical trials; risks that the
potential benefits of the agreements with our collaboration
partners may never be realized; risks that our products, and/or our
product candidates may be precluded from commercialization by the
proprietary or regulatory rights of third parties, or have
unintended side effects, adverse reactions or incidents of misuse;
risks associated with government and third-party regulatory and/or
policy efforts which may, among other things, impose sales and
pharmaceutical pricing controls on our products or limit coverage
and/or reimbursement for our products; risks associated with
competition from other therapies or products, including potential
generic entrants for our products; and other risks described in our
periodic reports filed with the Securities and Exchange Commission,
including our Annual Report on Form 10-K for the year ended
December 31, 2024. Neurocrine
Biosciences disclaims any obligation to update the statements
contained in this press release after the date hereof other than as
required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-board-of-directors-authorizes-500-million-share-repurchase-program-302382162.html
SOURCE Neurocrine Biosciences, Inc.
